Nanotechnology Now - Press Release: Starpharma secures European (EMA) agreement on BV treatment Phase 3

Home > Press > Starpharma secures European (EMA) agreement on BV treatment Phase 3

Abstract:
Starpharma (ASX: SPL; OCTQX: SPHRY) today announced that the Phase 3 clinical trial program for VivaGel® bacterial vaginosis (BV) treatment has now also been agreed with the European Medicines Agency (EMA).

Starpharma secures European (EMA) agreement on BV treatment Phase 3

Melbourne, Australia | Posted on November 21st, 2011

This European scientific advice is in addition to the agreement recently reached with the US Food and Drug Administration (FDA) announced by the Company on 10 October, 2011.

Starpharma recently presented to the EMA the proposed design of Phase 3 studies and associated aspects of the development program to support a (European) Marketing Authorisation Application (MAA) for VivaGel® for the treatment of BV. Following these discussions, Starpharma now has reached agreement on Phase 3 clinical trial design with the regulatory authorities for both the US and Europe.

The significance of the EMA feedback is that Starpharma has now confirmed for both major global markets - Europe and the US - that its Phase 3 program is acceptable, and positive results (as recently achieved for the Phase 2) would support approval of the product.

As previously announced, the company plans to commence its Phase 3 BV Treatment program early in 2012 with completion expected before year end. Following the completion of Phase 3 trials the company plans to partner the product.

These two Phase 3 studies will be conducted in parallel and the design - now agreed with both the FDA and EMA - is very similar to Starpharma's successful Phase 2 trial of VivaGel® for the treatment of BV. As for Starpharma's recently completed Phase 2 study, the primary endpoint in the Phase 3 trials will be Clinical Cure, as assessed by resolution of symptoms and other standard clinical criteria, and the comparator will be placebo gel.

"We are pleased that both the FDA and now the EMA have agreed with our proposed clinical program for BV treatment for Phase 3. We look forward to commencing the program early in the New Year and, following our recent financing, we plan to add some additional trial sites to further expedite its completion." said Starpharma Chief Executive Officer, Dr Jackie Fairley.

####

About Starpharma Holdings Limited
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer technology for pharmaceutical, life-science and other applications. SPL has two operating companies, Starpharma Pty Ltd in Melbourne, Australia and DNT, Inc in the USA. Products based on SPL’s dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents through licence arrangements with partners including Siemens and Merck KGaA.

The Company’s lead pharmaceutical development product is VivaGel® (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV, genital herpes and bacterial vaginosis. Starpharma has a licence agreement with Ansell Limited to develop a VivaGel®-coated condom, and a licence agreement with Okamoto Industries Inc in relation to the VivaGel®-coated condom for the Japanese market. Okamoto is the market leader for condoms sold in Japan, the world’s second largest condom market.

Starpharma also has agreements in place with Lilly, Elanco, Stiefel Laboratories (a GSK Company), and Siemens Healthcare as well as many research collaborations with some of the world’s leading organisations in the fields of pharmaceuticals, drug delivery, cosmetics and agrochemicals.
A dendrimer is a type of precisely-defined, branched nanoparticle. Dendrimers have applications in the medical, electronics, chemicals and materials industries.

American Depositary Receipts (ADRs): Starpharma’s ADRs trade under the code SPHRY (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Securities Exchange (ASX). Starpharma’s ADRs are listed on International OTCQX, a premium market tier in the U.S. for international exchange-listed companies.

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other health authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

For more information, please click here

Contacts:
Media:
Buchan Consulting
Rebecca Wilson
Mob: +61 417 382 391

Haley Price
Mob: +61 423 139 163

Starpharma:
Dr Jackie Fairley
Chief Executive Officer
+61 3 8532 2704

Ben Rogers
Company Secretary
+61 3 8532 2702